Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
Year: 2022
Type: article
Source: Blood
Authors: Claire Harrison, Jyoti Nangalia, Rebecca H. Boucher, Aimee Jackson, Christina Yap, Jennifer O'Sullivan, Sonia Fox, Isaak Ailts, Amylou C Dueck, Holly L. Geyer, Ruben Mesa, William Dunn, Eugene Nadezhdin, Natalia Curto-Garcia, Anna Green, Bridget Wilkins, Jason Coppell, John Laurie, Mamta Garg, Joanne Ewing, Steve Knapper, Josephine Crowe, Ioannis Koutsavlis, Anna L Godfrey, Siamak Arami, Mark W. Drummond, Jennifer Byrne, Fiona J Clark, Carolyn Mead-Harvey, Joanna E Baxter, Mary Frances McMullin, Adam J Mead
Institutions: Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, Wellcome/MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge University Hospitals NHS Foundation Trust, Wellcome Sanger Institute, Cancer Research UK Clinical Trials Unit, University of Birmingham, Institute of Cancer Research, University of Oxford, MRC Weatherall Institute of Molecular Medicine, Mayo Clinic in Arizona, The University of Texas at San Antonio Health Science Center, Mays Cancer Center at UT Health San Antonio, St Thomas' Hospital, Royal Devon and Exeter Hospital, Exeter Hospital, Worthing Hospital, University Hospitals Birmingham NHS Foundation Trust, Cardiff University, Royal United Hospital, Western General Hospital, London North West Healthcare NHS Trust, Beatson West of Scotland Cancer Centre, Nottingham University Hospitals NHS Trust, Queen Elizabeth Hospital Birmingham, Queen's University Belfast, Churchill Hospital, Oxford University Hospitals NHS Trust
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310125449